Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy with Day-and-Night In-Home Use Contact Information

PtID	1. Patient ID: CTR3
Namecode	2. Initials:
ayAndNightPhoneConf	tact
ontact Information	
PhCallDt	1. Contact Date: / / mm/dd/yy
NonPContType	2. Mode of Communication: ☐ Phone ☐ Text ☐ Email ☐ Office Visit
PrsnSpk	2. Person contacted: □Subject □Other
PrsnSpkDs	If Other, complete the following:
	Relationship to Subject:
CallerID	4. ID of Person Contacting Subject:
rior to completion of the contact o	during the initial trial period, the subject's data from previous day and night must be reviewed.
SystemUsed80Pct	1.Was the system used at least 80% of the time in closed-loop during the day and night? Note: Must be yes to qualify as a successful day of system use during 3-5 day trial period. □Yes □No □N/A, subject has progressed past 3-5 day trial period
	Did the subject have any significant problems with the system such as:
SystemProblems	Receiving any significant error messages related to meal bolusing, CGM calibration announcement, etc.
•	Responding to system alert messages

Identifying Information

	Extended loss of communication with remote monitoring
	Other aspects of the system operation
	□Yes □No
	a. If Yes, please describe:
SystemProblemsDs	
	
MeterHighOrLow	Did the subject have any occurrences of BG meter readings <50 mg/dl or >400 mg/dl in the absence of any infusion set failure?
	Yes No
MeterHighOrLowDs	b. If Yes, please describe:
SystemUseSuccess	In the opinion of the investigator, did the subject meet criteria for successful system use for this day?
	□Yes □No

Adverse Events Since Last Contact

Did the subject have a severe hypoglycemic episode requiring assistance of another person to administer carbohydrate, glucagon or other resuscitative actions not already reported?
☐Yes ☐No (If Yes, complete a Severe Hypo Event Form)
Did the subject have a DKA not already reported?
☐Yes ☐No (If Yes, complete a DKA Event Form)
DKA is defined as follows by the DCCT, and has all of the following:

Symptoms such as polyuria, polydipsia, nausea, or vomiting;

Serum ketones or large/moderate urine ketones;

Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and

Treatment provided in a health care facility

Have any adverse events or any unexpected medical occurrence that is study or device related occurred that has not already been reported?

Yes No (If Yes, complete an Adverse Event Form)

AdverseEvent